

Program Schedule 13th European HIV & Hepatitis Workshop

version: 15-5-2015

Wednesday 3 June

Session 1: Educational Session on HCV and HIV

09.00 **Opening of the Workshop**

09.15 **HCV related cancerogenesis**

Francesca Ceccherini-Silberstein

09.45 **Pan-European HCV Treatment on HIV infected patients from a clinical point of view**

Patrick Ingiliz

10.15 **Clinical Cases: HIV and HCV co-infection**

**Annemarie Wensing
Valentina Svicher**

11.00 Coffee Break

Session 2: Future Directions of HIV Therapy (I)

Chairs: Jonathan Schapiro & Jens Verheyen

11.30 **Long acting ARV compounds (nano formulation)**

Courtney Fletcher

12.00 **Gene therapy approaches towards a HIV Cure**

Monique Nijhuis

12.30 **Clinical cases: HIV**

Roger Paredes

13.00 Lunch

Session 3: Current HIV Treatment strategies

Chairs: Roger Paredes & Nicola Mackie

14.00 **Viro-immunological response to treatment of naïve HIV-1 positive patients with viral load > 500,000 copies / ml: a personalized treatment is needed?**

Sterrantino #1

14.10 **Children age, antiretroviral treatment and CD4 count are major determinants of HIV-1B evolution in pediatric patients**

Rojas-Sánchez #2

14.20 **Evolution of HIV-1 drug resistance in patients failing a standard thymidine analogue-based first-line ART: implications for the activity of next-line regimens from a longitudinal study in Mozambique.**

De Luca #3

14.30 **Integrated HIV-1 DNA load during stably suppressive antiretroviral therapy is associated with the frequency of CD8 cells expressing HLA-DR/DP/DQ**

Geretti #4

14.40 **Comprehensive longitudinal characterization of HIV-1 reservoir markers in patients on stable antiretroviral treatment**

Kiselinova #5

14.50 **Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)**

Underwood #6

15.00 **Viro-immunological efficacy and tropism evolution in treatment-experienced HIV-1 infected patients starting maraviroc in clinical practice**

Di Carlo #7

15.10 **The HIV1 reverse transcriptase E138A polymorphism decreases the genetic barrier to resistance to etravirine in vitro**

Saladini #8

15.20 **Comparison of two-drug combination passage in vitro for drug resistance emergence among dolutegravir, rilpivirine, elvitegravir and 3TC**

Yoshinaga #9

15.30 **Discussion**

15.45 Coffee Break

Session 4: Determinants of HBV Pathogenesis

Chairs: Anna Maria Geretti & Christophe Rodriguez

16.15 **Virological Perspective**

Fabien Zoulim

16.45 **Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection**

Vergori #10

16.55 **Genetic elements clustered in specific immune active HBsAg regions drive HBV reactivation under immunosuppression: an extensive analysis of HBV genome**

Salpini #11

17.05 **A hyper-glycosylation in HBsAg characterizes immunosuppression-driven HBV reactivation and affects HBsAg recognition and quantification in vitro**

Colagrossi #12

17.15 **Key genetic elements in HBsAg significantly correlate with liver cancer onset by hampering HBsAg secretion and promoting cell proliferation in vitro**

Surdo #13

17.25 **Clinical Case: HBV reactivation upon immunosuppression**

Claudia Alteri

18.00 Welcome Reception & Poster Viewing

Thursday 4 June

08.30 Industry - sponsored symposium

Session 5: Viral Diagnostics in 2020

Chairs: Anne Wensing & Hauke Walter

- 09.30 How Genotypic Resistance Test in PBMC (Proviral DNA) May Help to Identify Hidden Resistance in patients with Low Level or Undetectable HIV-RNA? Zaccarelli #14
- 09.40 Improvement of HIV resistance testing by proviral DNA analysis and Next Generation Sequencing Lübke #15
- 09.50 Impact of hypermutation on the results of deep sequencing analysis of proviral DNA for baseline HIV-1 drug resistance Dauwe #16
- 10.00 European guidance on clinical management of HIV low level viremia Hofstra #17
- 10.15 **Panel Discussion**

11.00 Coffee Break

Special session Keys to optimal use of integrase inhibitors in clinical practice

- 11.30 Transmission of (Primary) Drug Resistance Charles Boucher
- 12.00 Clinical relevant Drug Interactions Saye Khoo
- 12.30 Translation to Clinical Management Jonathan Schapiro

13.00 Lunch

13.45 Poster Viewing session (1 hour)

10th Int. Workshop on HEPATITIS C - Resistance & New Compounds

Session 6: Drug Resistance to HCV DAA's

Chairs: Stefan Zeuzem & Andrea DeLuca

- 14.45 Drug Resistance to NS5a/b Inhibitors Chris Petropoulos
- 15.15 Drug Resistance to Protease Inhibitors Francesca Ceccherini-Silberstein
- 15.45 European Registry of Hepatitis C Resistance Charles Boucher

16.00 Coffee Break

session 7: Main Challenges in HCV

Chairs: Chris Petropoulos & Francesca Ceccherini-Silberstein

- 16.30 Future treatment strategies for Hepatitis C Stefan Zeuzem
- 17.00 Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus (HCV) genotype 1a strains in the United Kingdom Beloukas #18
- 17.15 Retreatment with an interferon-free combination of simeprevir-sofosbuvir in patients who had previously failed on HCV NS5A inhibitor-based regimens Hezode #19
- 17.30 Comparison of two HCV-RNA assays assessing early response to simeprevir+PegIFN/RBV to select patients suitable to shorten therapy to 12 weeks Gschwantler #20
- 17.40 Comparison of three commercial platforms for Hepatitis C Virus Genotyping and NS5B sequencing. GEHEP-007 study. Garcia #21
- 17.50 Relevance of Hepatitis C Virus Sequencing for Genotype and Subtype Determination in the Era of New Direct Antiviral Agents Di Maio #22

18.00 End of Program day 2

Friday 5 June

session 8: Induction Maintenance revisited in Antiretroviral Therapy

Chairs: Bonaventura Clotet & Rolf Kaiser

08.30 **The Clinical Evidence**

Andrea DeLuca

08.55 **The Virological Support**

Charles Boucher

09.20 **Clinical Case**

Linus Vandekerckhove

09.45 **Round table Discussion**

10.00 **Coffee Break**

Session 9: HIV Epidemiology

Chairs: Annemie Vandamme & Leon Kostrikis

10.30 The global spread of HIV-1 subtype A epidemic: a phylogeographic analysis

Paraskevis #23

10.40 Study of Transmitted Drug Resistance among Men having Sex with Men and African Heterosexual Population: Interest of UltraDeep Sequencing

Todesco #24

10.50 Patients infected with CRF02_AG are more likely to experience virological rebound under first line PI/r based HAART.

Armenia #25

11.00 Transmission of Drug Resistance in Europe: Overview of SPREAD Surveillance Program

Marije Hofstra

Session 10: Future Directions of HIV Therapy (II)

Chairs: Linus Vandekerckhove & Charles Boucher

11.15 **Penetration of cART in residual sites**

Courtney Fletcher

11.45 **Re-activation of the latent reservoir**

David Margolis

12.15 **Provirus viability**

Chris Petropoulos

12.45 **Round table discussion**

13.00 **End of meeting**